ISPC vs LLY · rev $9.3M vs P/E 39, rev $65.18B
iSpecimen Inc (ISPC) versus Eli Lilly and Company (LLY) — a side-by-side from cached financials, not a winner call.
iSpecimen Inc (ISPC) is a diagnostics & research company listed on US.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David Ricks.
Latest reported ISPC revenue for 2024-12-31 was $9.3M. Net income was -$12.5M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. ISPC currently screens at market cap $4.4M.
Latest reported LLY revenue for 2025-12-31 was $65.18B. Net income was $20.64B. Revenue was up 44.7% from 2024-12-31 to 2025-12-31. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
ISPC currently screens at market cap $4.4M. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
Not investment advice. Open the ISPC and LLY stock pages for the full models.
Not investment advice.